Examqo › Examqo library › Cardiothoracic surgery › Lung cancer surgery · IMLE
Pulmonary metastasectomy
Lung metastasectomy suits a patient whose primary tumour is controlled, who has no disease outside the chest (or it is controllable), and in whom all metastases can be removed while preserving respiratory reserve; the best prognosis is with complete resection, a long disease-free interval and a single metastasis, and the clearest benefit is in sarcomas and germ cell tumours.
Why it matters in the exam
The lung is a common target for metastases, and sometimes it is the only site of disease — so resection may prolong life. The classic criteria for selecting a candidate: the primary tumour is controlled or controllable; there is no disease outside the chest, or it can be treated locally; all lesions can be removed; the patient has adequate respiratory reserve; and there is no better treatment. Data from the international registry (IRLM, 1997) showed three favourable factors: complete resection, a disease-free interval of 36 months or more, and a single metastasis. Incomplete resection is of no benefit, so if it is clear beforehand that not all lesions will be removed — there is no point operating.
By tumour type: in osteosarcoma and soft tissue sarcomas metastasectomy is a central part of treatment and improves survival; in germ cell tumours a residual mass after chemotherapy is removed, since it may harbour teratoma or active tumour; in colorectal and renal cancer surgery is accepted in selected patients, although the PulMiCC trial (2020) did not prove a clear survival benefit, so the decision is multidisciplinary. Technique: parenchyma-sparing wedge resections with clear margins; lobectomy only when the lesion is central. Manual palpation in open surgery sometimes finds lesions not seen on CT, but VATS is accepted when imaging is of good quality. Repeat resections are possible when new metastases appear, and non-surgical alternatives are SBRT and ablation.
Before the decision an up-to-date chest CT, PET-CT according to tumour type, and functional lung assessment are done.
Key points
- Primary controlled, no other disease, complete resection possible.
- Complete resection is the key factor.
- An interval of 36 months or more — favourable.
- Sarcoma and germ cell — clear benefit.
- Parenchyma-sparing wedge resection.
Summary table
| Factor | Meaning | Note |
|---|---|---|
| Complete resection | The most important prognostic factor | Incomplete resection is of no benefit |
| Disease-free interval | 36 months or more — better | Indicates slow biology |
| Number of metastases | A single metastasis — better | No absolute numerical limit |
| Tumour type | Sarcoma and germ cell — clear benefit; colorectal — selected patients | PulMiCC did not prove a clear benefit |
| Technique | Wedge resection with clear margins | SBRT or ablation as alternatives |
A free exam question
מה מהבאים נכון לגבי גידולים גרורתיים )METASTATIC( בלב? (the question as examined, in Hebrew)
- א. גרורות בלב הן בדרך כלל בודדות ונדיר לראות פיזור נרחב
- ב. מבין הגידולים הראשונים – Melanoma הינו הנפוץ ביותר, השולח גרורות ללב
- ג. הפיזור הגרורתי ללב מ- Bronchogenic Carcinoma הוא בדרך כלל המטוגני ולבסוף דרך העורקים הכליליים
- ד. 4 קיימת קליניקה בכ – 50% מהחולים עם גרורות לבביות, כאשר הפרזנטציה הינה בדרך כלל תפליט פריקרדיאלי או טמפונדה
In the full version for subscribers
- A simple algorithm
- Memory aid
- Exam traps
- 5 review cards
- Enough for IMLE
The full version is open to subscribers of: Cardiothoracic surgery, General surgery, Oncology, Medical licensing exam (IMLE).
Subscriber? Read the full topic Plans and prices 25 free questions
Sources
- ESMO–EURACAN–GENTURIS Clinical Practice Guideline: Soft tissue and visceral sarcomas, 2021 — Management of metastatic disease
- International Registry of Lung Metastases, J Thorac Cardiovasc Surg, 1997 — Long-term results of lung metastasectomy
- NCCN Clinical Practice Guidelines in Oncology: Bone Cancer and Soft Tissue Sarcoma, 2025 — Management of pulmonary metastases
Sources are given for further reading; the text is written afresh and not copied from them.
Reviewed by the Examqo AI Professor · 2026-11-06. The text may contain errors; when in doubt, check the source.